Abstract
A series of sixteen N-(trans)-3-phenylprop-2-en-1-yl (cinnamyl) derivatives of various aminoalkanols was synthesized and evaluated for anticonvulsant activity and neurotoxicity. In preliminary evaluation three standard tests in mice after intraperitoneal administration were used: maximal electroshock (MES), subcutaneous pentetrazol, and rotarod test. Fifteen compounds showed some protection in MES. Next step included evaluation in rats after oral administration. The most promising compound, (R,S)-2-{[(trans)-3-phenylprop-2-en-1-yl]amino}propan-1-ol hydrochloride (1a), was also tested in model of pilocarpine-induced status prevention, 6-Hz test, and in vitro neuroprotection evaluation. Additionally, for selected compounds experimental pKa values were determined as well as serotonin receptors (5-HT1A, 5-HT6, and 5- HT7) binding affinities were found. None of the tested compounds showed significant binding affinity to serotonin receptors. However, in vivo pharmacological results indicated that further modification of the structures might lead to discovering new potential anticonvulsants.
Keywords: Aminoalkanols, Anticonvulsant, Cinnamyl, Epilepsy, Maximal electroshock, Pentetrazol.
Letters in Drug Design & Discovery
Title:Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols
Volume: 11 Issue: 8
Author(s): Agnieszka Gunia-Krzyzak, Anna M. Waszkielewicz, Karolina Sloczynska, Magda Borczuch- Kostanska, Marek Cegla, Grzegorz Satala, Andrzej J. Bojarski and Henryk Marona
Affiliation:
Keywords: Aminoalkanols, Anticonvulsant, Cinnamyl, Epilepsy, Maximal electroshock, Pentetrazol.
Abstract: A series of sixteen N-(trans)-3-phenylprop-2-en-1-yl (cinnamyl) derivatives of various aminoalkanols was synthesized and evaluated for anticonvulsant activity and neurotoxicity. In preliminary evaluation three standard tests in mice after intraperitoneal administration were used: maximal electroshock (MES), subcutaneous pentetrazol, and rotarod test. Fifteen compounds showed some protection in MES. Next step included evaluation in rats after oral administration. The most promising compound, (R,S)-2-{[(trans)-3-phenylprop-2-en-1-yl]amino}propan-1-ol hydrochloride (1a), was also tested in model of pilocarpine-induced status prevention, 6-Hz test, and in vitro neuroprotection evaluation. Additionally, for selected compounds experimental pKa values were determined as well as serotonin receptors (5-HT1A, 5-HT6, and 5- HT7) binding affinities were found. None of the tested compounds showed significant binding affinity to serotonin receptors. However, in vivo pharmacological results indicated that further modification of the structures might lead to discovering new potential anticonvulsants.
Export Options
About this article
Cite this article as:
Gunia-Krzyzak Agnieszka, Waszkielewicz M. Anna, Sloczynska Karolina, Borczuch- Kostanska Magda, Cegla Marek, Satala Grzegorz, Bojarski J. Andrzej and Marona Henryk, Synthesis and Anticonvulsant Activity of N-(trans)- 3-phenylprop-2-en-1-yl (Cinnamyl) Derivatives of Aminoalkanols, Letters in Drug Design & Discovery 2014; 11(8) . https://dx.doi.org/10.2174/1570180811666140423203639
DOI https://dx.doi.org/10.2174/1570180811666140423203639 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson’s Disease and Huntington’s Disease: A Review
Current Neuropharmacology PLGA Nanoparticles for Nose to Brain Delivery of Clonazepam: Formulation, Optimization by 32 Factorial Design, In Vitro and In Vivo Evaluation
Current Drug Delivery Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry Autonomic Nervous System Alterations in Rett Syndrome
Current Pediatric Reviews Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging
Current Medicinal Chemistry Physiology, Pharmacology and Pathophysiology of the pH Regulatory Transport Proteins NHE1 and NBCn1: Similarities, Differences, and Implications for Cancer Therapy
Current Pharmaceutical Design MG17, A Novel Triazole Derivative Abrogated Neuroinflammation and Related Neurodegenerative Symptoms in Rodents
Current Molecular Pharmacology Pharmacogenetics of the Human MDR1 Multidrug Transporter
Current Pharmacogenomics Nanoparticulate Drug Delivery in Pregnancy: Placental Passage and Fetal Exposure
Current Pharmaceutical Biotechnology The Function of LncRNA FTX in Several Common Cancers
Current Pharmaceutical Design The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Biological and Chemical Aspects of Natural Biflavonoids from Plants: A Brief Review
Mini-Reviews in Medicinal Chemistry The Role of T-Type Calcium Channels in Epilepsy and Pain
Current Pharmaceutical Design Free Radicals in Living Systems: In Vivo Detection of Bioradicals with EPR Spectroscopy
Current Organic Chemistry Oxidative Stress-Induced Caspases are Regulated in Human Myeloid HL-60 Cells by Calcium Signal
Current Signal Transduction Therapy New Route to Synthesize Fluorine Substituted Lamotrigine Drug Analogues as an Anti-Inflammatory Agent
Current Organic Synthesis Design, Synthesis and Anticonvulsant Activity Evaluation of 7-Substituted –[1,2,4]-Triazolo[4,3-f]Pyrimidine Derivatives
Medicinal Chemistry Editorial (Thematic Issue: Polypharmacology in Drug Discovery)
Current Pharmaceutical Design Kv1.5-Kvβ Interactions: Molecular Determinants and Pharmacological Consequences
Mini-Reviews in Medicinal Chemistry